Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial - Bartlett, J MS; Munro, A; Cameron, D A (J Clin Oncol, 2008)
et al.